Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) EBT (2016 - 2025)

Historic EBT for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to -$2.9 million.

  • Palisade Bio's EBT rose 1867.19% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 2168.81%. This contributed to the annual value of -$14.9 million for FY2024, which is 1364.92% down from last year.
  • As of Q3 2025, Palisade Bio's EBT stood at -$2.9 million, which was up 1867.19% from -$2.8 million recorded in Q2 2025.
  • Palisade Bio's EBT's 5-year high stood at -$2.3 million during Q1 2025, with a 5-year trough of -$33.5 million in Q2 2021.
  • In the last 5 years, Palisade Bio's EBT had a median value of -$3.6 million in 2023 and averaged -$5.1 million.
  • In the last 5 years, Palisade Bio's EBT plummeted by 171888.15% in 2021 and then surged by 8932.65% in 2022.
  • Quarter analysis of 5 years shows Palisade Bio's EBT stood at -$3.0 million in 2021, then fell by 26.59% to -$3.9 million in 2022, then grew by 18.0% to -$3.2 million in 2023, then dropped by 7.19% to -$3.4 million in 2024, then rose by 13.53% to -$2.9 million in 2025.
  • Its last three reported values are -$2.9 million in Q3 2025, -$2.8 million for Q2 2025, and -$2.3 million during Q1 2025.